Research platform enables biotech startups to outsource everything
but the genius
SAN DIEGO–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/fasterscience?src=hash" target="_blank"gt;#fastersciencelt;/agt;–Scientist.com, the world’s largest marketplace for outsourced R&D
services, today announced a partnership with 5AM Ventures, a leading
venture capital firm focused on building next-generation life science
companies. Over 70 companies associated with 5AM can now use a
5AM-branded R&D marketplace that simplifies research outsourcing, saves
time and money, and provides access to the latest innovative research
tools and technologies.
“The 4:59 Initiative is the internal company creation effort within 5AM
that conceives, builds, and funds breakthrough science and establishes
early, proof-of-principle data that enables Series A financing,” said
Andy Schwab, 5AM Managing Partner. “By providing rapid and
cost-effective access to services and experts, the 5AM R&D marketplace
allows our seed and early-stage companies to compete head-to-head with
pharma companies that are a thousand times their size.”
Start-up companies are increasingly pursuing a virtual approach to
medical research in which most R&D is outsourced to external CROs. R&D
marketplaces like Scientist.com make it easy for start-up company
researchers to connect with experts, design experiments and then
purchase outsourced R&D services on demand.
“Through the R&D marketplace created with Scientist.com, the 5AM
portfolio can engage with pre-clinical and clinical research services
and connect with hundreds of industry-leading experts,” stated Kevin
Lustig, PhD, Scientist.com’s CEO and Founder. “A small experienced team
of drug hunters or even a single person can now run research projects
that ten years ago would have required the concerted effort of hundreds
of pharmaceutical researchers.”
About Scientist.com
Scientist.com is the world’s leading marketplace for outsourced R&D. The
marketplace simplifies R&D sourcing, saving time and money, reducing
risk and providing access to the latest innovative tools and
technologies. Scientist.com operates private enterprise marketplaces for
most of the world’s major pharmaceutical companies, the Biotechnology
Innovation Organization (BIO) and the US National Institutes of Health
(NIH). Since its founding in 2007, Scientist.com has raised $32 million
from Leerink Transformation Partners, 5AM Ventures and Heritage Provider
Network among others. Visit scientist.com
to learn more.
Join Scientist.com on social media: YouTube,
LinkedIn,
Twitter,
Facebook
and Instagram.
About 5AM Ventures
Founded in 2002, 5AM actively invests in next-generation biotech
companies. With approximately $1.5 billion raised since inception, 5AM
has invested in 77 companies including Arvinas (NASDAQ: ARVN), Audentes
Therapeutics (NASDAQ: BOLD), Crinetics Pharmaceuticals (NASDAQ: CRNX),
Flexion Therapeutics (NASDAQ: FLXN), Homology Medicines (NASDAQ: FIXX),
Ikaria (acquired by Mallinckrodt), Ilypsa (acquired by Amgen), Marcadia
Biotech (acquired by Roche), Novira Therapeutics (acquired by J&J),
Pearl Therapeutics (acquired by AstraZeneca) Relypsa (acquired by Vifor
Pharma) and Ideaya Biosciences (NASDAQ: IDYA). For more information,
please visit www.5amventures.com.
Contacts
Sean Preci
Director of Communications, Scientist.com
+1 858
455-1300 ext. 401
marketing@scientist.com
Britt Inga Emerson
5AM Ventures
info@5amventures.com